X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (86) 86
Patent (9) 9
Book / eBook (3) 3
Publication (3) 3
Book Chapter (2) 2
Dissertation (2) 2
Book Review (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (34) 34
humans (32) 32
oncology (24) 24
female (18) 18
male (18) 18
middle aged (12) 12
aged (11) 11
animals (11) 11
cancer (11) 11
mutation (10) 10
lung neoplasms - drug therapy (9) 9
docetaxel (8) 8
lung cancer (8) 8
mice (8) 8
nivolumab (8) 8
adult (7) 7
basic electric elements (7) 7
cell line, tumor (7) 7
chemotherapy (7) 7
electricity (7) 7
lung neoplasms - genetics (7) 7
lung neoplasms - pathology (7) 7
measuring (7) 7
measuring electric variables (7) 7
measuring magnetic variables (7) 7
non-small cell lung cancer (7) 7
physics (7) 7
processes or means, e.g. batteries, for the direct conversionof chemical into electrical energy (7) 7
protein kinase inhibitors - pharmacology (7) 7
testing (7) 7
analysis (6) 6
antineoplastic agents - therapeutic use (6) 6
carcinoma, non-small-cell lung - drug therapy (6) 6
carcinoma, non-small-cell lung - genetics (6) 6
care and treatment (6) 6
cell proliferation - drug effects (6) 6
chemistry, multidisciplinary (6) 6
lung cancer, non-small cell (6) 6
non–small cell lung cancer (6) 6
receptor, epidermal growth factor - genetics (6) 6
apoptosis - drug effects (5) 5
carcinoma, non-small-cell lung - pathology (5) 5
epidermal growth factor (5) 5
genetic aspects (5) 5
metastasis (5) 5
mutations (5) 5
resistance (5) 5
treatment outcome (5) 5
xenograft model antitumor assays (5) 5
antineoplastic agents - pharmacology (4) 4
breast cancer (4) 4
drug combinations (4) 4
epidermal growth factor receptors (4) 4
erbb-2 protein (4) 4
expression (4) 4
gefitinib (4) 4
inhibitor (4) 4
inhibitors (4) 4
liver (4) 4
molecular targeted therapy (4) 4
patients (4) 4
respiratory system (4) 4
risk factors (4) 4
survival (4) 4
tomography, x-ray computed (4) 4
adenocarcinoma (3) 3
adenocarcinoma - drug therapy (3) 3
aged, 80 and over (3) 3
antibodies, monoclonal - therapeutic use (3) 3
apoptosis (3) 3
breast neoplasms - drug therapy (3) 3
carcinoma, squamous cell - pathology (3) 3
case report (3) 3
clinical neurology (3) 3
disease (3) 3
dose-response relationship, drug (3) 3
drug resistance, neoplasm (3) 3
drug resistance, neoplasm - drug effects (3) 3
drug resistance, neoplasm - genetics (3) 3
drug-resistance (3) 3
enzymes (3) 3
epidermal growth factor receptor (3) 3
follow-up studies (3) 3
gene amplification (3) 3
genetic research (3) 3
growth-factor receptor (3) 3
guidelines (3) 3
her2 (3) 3
insertion (3) 3
kinases (3) 3
lung-cancer (3) 3
magnetic resonance imaging (3) 3
medicine & public health (3) 3
mice, nude (3) 3
original (3) 3
pharmacology & pharmacy (3) 3
prevalence (3) 3
prognosis (3) 3
quinazolines - therapeutic use (3) 3
receptor, epidermal growth factor - antagonists & inhibitors (3) 3
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


CLINICAL CANCER RESEARCH, ISSN 1078-0432, 09/2015, Volume 21, Issue 17, pp. 4014 - 4021
Journal Article
Proceedings of the National Academy of Sciences, ISSN 0027-8424, 11/2014, Volume 111, Issue 45, pp. E4869 - E4877
The human FGF receptors (FGFRs) play critical roles in various human cancers, and several FGFR inhibitors are currently under clinical investigation.... 
Structure-based drug design | Drug discovery | Cancer drug resistance | Kinase inhibitor | structure-based drug design | WILD-TYPE | MULTIDISCIPLINARY SCIENCES | BCR-ABL | GROWTH-FACTOR RECEPTORS | DRUG-RESISTANCE | kinase inhibitor | LUNG-CANCER | GENE FUSIONS | cancer drug resistance | SELECTIVE INHIBITOR | drug discovery | THERAPEUTIC TARGET | FACTOR RECEPTOR 4 | REGULATES PROLIFERATION | Receptor, Fibroblast Growth Factor, Type 4 - chemistry | Receptor, Epidermal Growth Factor - genetics | Receptor, Fibroblast Growth Factor, Type 4 - metabolism | Receptor, Fibroblast Growth Factor, Type 2 - chemistry | Receptor, Fibroblast Growth Factor, Type 2 - metabolism | Humans | Receptor, Fibroblast Growth Factor, Type 1 - metabolism | Crystallography, X-Ray | Structure-Activity Relationship | Mutation, Missense | Receptor, Fibroblast Growth Factor, Type 1 - genetics | Protein Kinase Inhibitors - chemistry | Receptor, Epidermal Growth Factor - metabolism | Neoplasms - genetics | Receptor, Fibroblast Growth Factor, Type 2 - antagonists & inhibitors | Antineoplastic Agents - pharmacology | Receptor, Fibroblast Growth Factor, Type 4 - genetics | Binding Sites | Neoplasms - enzymology | Antineoplastic Agents - chemistry | Receptor, Fibroblast Growth Factor, Type 1 - antagonists & inhibitors | Receptor, Epidermal Growth Factor - chemistry | Neoplasms - drug therapy | Drug Resistance, Neoplasm - genetics | Cell Line, Tumor | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Protein Kinase Inhibitors - pharmacology | Receptor, Fibroblast Growth Factor, Type 1 - chemistry | Neoplasms - pathology | Receptor, Fibroblast Growth Factor, Type 4 - antagonists & inhibitors | Receptor, Fibroblast Growth Factor, Type 2 - genetics | Amino Acid Substitution | Drug Resistance, Neoplasm - drug effects | Amino acids | T cell receptors | Mutation | Kinases | Binding sites | Adenosine triphosphatase | Index Medicus | Biological Sciences | PNAS Plus
Journal Article
Cancer Research, ISSN 0008-5472, 05/2017, Volume 77, Issue 10, pp. 2712 - 2721
Insertion mutations in EGFR and HER2 both occur at analogous positions in exon 20. Non-small cell lung cancer (NSCLC) patients with tumors harboring these... 
CELL LUNG-CANCER | TYROSINE KINASE INHIBITORS | GROWTH-FACTOR RECEPTOR | 1ST-LINE TREATMENT | ONCOLOGY | ADENOCARCINOMAS | RESISTANCE | OPEN-LABEL | MUTATIONS | TUMORS | CHEMOTHERAPY | Lung Neoplasms - drug therapy | Receptor, Epidermal Growth Factor - genetics | Receptor, ErbB-2 - genetics | Exons | Humans | Middle Aged | Molecular Conformation | Receptor, ErbB-2 - chemistry | Male | Tomography, X-Ray Computed | Antineoplastic Agents - therapeutic use | Dose-Response Relationship, Drug | Protein Kinase Inhibitors - chemistry | Codon | Adult | Female | Antineoplastic Agents - pharmacology | Receptor, ErbB-2 - antagonists & inhibitors | Disease Models, Animal | Lung Neoplasms - genetics | Gene Expression | Models, Molecular | Treatment Outcome | Antineoplastic Agents - chemistry | Receptor, Epidermal Growth Factor - chemistry | Xenograft Model Antitumor Assays | Drug Resistance, Neoplasm - genetics | Animals | Protein Kinase Inhibitors - therapeutic use | Cell Line, Tumor | Protein Binding | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Mice | Mutagenesis, Insertional | Protein Kinase Inhibitors - pharmacology | Lung Neoplasms - diagnosis | Amino Acid Substitution | Epidermal growth factor receptors | Lung cancer | Insertion | Drug resistance | Patients | ErbB-2 protein | Mutants | Sensitivity | Covalence | Inhibitors | Mutation | Tumors | Cancer | Index Medicus | human epidermal growth factor receptor 2 | drug resistance | tyrosine kinase inhibitor | exon 20 | Epidermal growth factor receptor
Journal Article
Journal Article
Journal Article
Investigational New Drugs, ISSN 0167-6997, 8/2017, Volume 35, Issue 4, pp. 529 - 536
Background Nivolumab demonstrates promising efficacy for the treatment of non-small cell lung cancer and other malignancies. The clinical benefit of nivolumab,... 
Medicine & Public Health | Cholangitis | Oncology | Nivolumab monotherapy | Pharmacology/Toxicology | Immune-related adverse event | Programmed death-1 | ANTI-PD-L1 ANTIBODY | MELANOMA | DISEASES | ONCOLOGY | SAFETY | PHARMACOLOGY & PHARMACY | DOCETAXEL | MPDL3280A | Carcinoma, Non-Small-Cell Lung - pathology | Lung Neoplasms - drug therapy | Cholangitis - chemically induced | Liver - pathology | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Antibodies, Monoclonal - therapeutic use | Lung Neoplasms - pathology | Male | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - adverse effects | Liver - diagnostic imaging | Aged, 80 and over | Cholangitis - diagnostic imaging | Female | Lung Neoplasms - diagnostic imaging | Aged | Carcinoma, Non-Small-Cell Lung - diagnostic imaging | Carcinoma, Non-Small-Cell Lung - drug therapy | Cholangitis - pathology | Care and treatment | Research | Diagnosis | Lung cancer, Non-small cell | Risk factors | Biliary tract | Therapy | Alkaline phosphatase | Intravenous administration | g-Glutamyltransferase | Identification methods | Liver | Lung | Lung cancer | Medical services | Parenchyma | Smooth muscle | Lymphocytes T | Metastases | Immunology | Search methods | Etiology | Enzymes | Alanine | Abnormalities | Markers | Non-small cell lung carcinoma | Immunoglobulin G4 | Patients | Bile duct | Hepatocytes | Biopsy | Alanine transaminase | Infiltration | Differentiation | Hypertrophy | Cancer | Bile | Index Medicus
Journal Article
Journal of Thoracic Oncology, ISSN 1556-0864, 01/2018, Volume 13, Issue 1, pp. 97 - 105
Journal Article
Cancer Science, ISSN 1347-9032, 11/2016, Volume 107, Issue 11, pp. 1667 - 1676
Journal Article
Journal Article
Journal of Thoracic Oncology, ISSN 1556-0864, 05/2018, Volume 13, Issue 5, pp. e86 - e87
Journal Article
Journal of Thoracic Oncology, ISSN 1556-0864, 05/2018, Volume 13, Issue 5, pp. e86 - e87
Journal Article
Journal of Thoracic Oncology, ISSN 1556-0864, 05/2018, Volume 13, Issue 5, pp. e86 - e87
Journal Article
Journal of Thoracic Oncology, ISSN 1556-0864, 05/2018, Volume 13, Issue 5, pp. e86 - e87
Journal Article
Molecular Cancer Therapeutics, ISSN 1535-7163, 06/2010, Volume 9, Issue 6, pp. 1647 - 1656
Journal Article
Journal Article